RIPK1-IN-7

• UNSPSC Description:

  RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model[1].

• Target Antigen:

  RIP kinase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ripk1-in-7.html

• Purity:

  98.56

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles:

  NC1=C2C(N(CC)C=C2C3=CC(CCN4C(CC5=CC=CC(OC(F)(F)F)=C5)=O)=C4C=C3)=NC=N1

• Molecular Weight:

  481.47

• References & Citations:

  [1]Li Y, et al. Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. J Med Chem. 2018 Dec 27;61(24):11398-11414.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2300982-44-7